{"disease":{"id":"grade-2-astrocytoma","name":"Grade 2 astrocytoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"vorasidenib","indication_name":"Grade 2 astrocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voranigo","generic_name":"VORASIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06809322","title":"Vorasidenib Maintenance for IDH Mutant Astrocytoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":468,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT04576117","title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03243461","title":"International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":167,"lead_sponsor_name":"University of Göttingen","has_results":false},{"nct_id":"NCT03528642","title":"Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06860594","title":"Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07286292","title":"Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institut de Recherches Internationales Servier (I.R.I.S.)","has_results":false}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}